newsfilter
← Latest News
GlobeNewswire·

Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with selection of final formulation completed and engagem